BioReperia has developed a unique zebrafish tumor xenograft (ZTX™) technology platform that provides functional in-vivo data to evaluate treatment efficacy for tumor regression and metastasis inhibition in only 5 days.
Our goal is to increase the speed and accuracy of preclinical drug development for cancer treatment, enabling you to select the lead candidates with the highest potential to succeed in less time.
We are happy to introduce LSI Epsilons 9th investment Abarceo Pharma AB, a pre-clinical stage company, developing a platform for the treatment of mitochondrial diseases, with an initial focus on Type 2 Diabetes (T2D).We look forward to work closely with Adam Bruce,...
So excited to introduce our 8th investment. SampleFacts is reinventing blood 🩸 sampling by separating blood and plasma instantly. We look forward to work closely with Maryam Poorafshar, Kristina Svensson, Frida Ekholm, Ulf Landegren, Jon-Sverre Schanche and rest of...
Glad to introduce our seventh investment Bioservo AB. Bioservo is a world-leading company within wearable grip-strengthening systems. Looking forward to work with Petter Bäckgren, Mikael Wester, Philip Simonson, Annika Rydgård and rest of the team. Listen to Petter...